Ivabradine in Patients With Congestive Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-06-01

Study Completion Date

2021-02-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the efficacy of Ivabradine therapy in patients with congestive heart failure using the cardiac biomarkers NT-Pro BNP and Neopterin.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Ivabradine to Reduce Heart Rate Prior to Coronary CT-angiography in Advanced Heart Failure: Comparison With β-Blocker

NCT03830957

Heart Failure CT Angiography Ischemic Cardiomyopathy +5 more

UNKNOWN NA

Pharmacokinetic Drug-Drug Interaction Between Bisoprolol and Ivabradine in Healthy Volunteers

NCT03485482

Cardiovascular Diseases

COMPLETED PHASE3

Role of Ivabradine for Heart Rate Control in Management of Patients With Sepsis and Septic Shock

NCT06742164

Heart Rhythm Disorder

NOT_YET_RECRUITING NA

Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI

NCT04285736

NSTEMI

COMPLETED PHASE2/PHASE3

Effect of Ivabradine on Heart Rate & Effort Tolerance in Mitral Stenosis in Sinus Rhythm

NCT01022463

Mitral Stenosis

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Approval will be obtained from Research Ethics Committee of Faculty of Pharmacy, Damanhour University
* All participants have agreed to take part in this clinical study and provide informed consent
* A 3 months, prospective interventional study.
* Sixty ambulatory, clinically stable symptomatic patients with systolic chronic HF (≥ 4 weeks), on optimized standard medical therapy were consecutively included and randomly allocated to the ivabradine group (n=30) and non-ivabradine group (n=30).
* The baseline evaluation comprised physical examination, NYHA class, 12-lead electrocardi¬ography (ECG), Echocardiography, blood sampling for laboratory measurements, including NT-Pro BNP and Neopterin.
* Patients in the Ivabradine group were administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.
* Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study.
* Peripheral venous blood samples were drawn between 8 and 9 am after a 30-min rest in the supine position. Serum samples were frozen at -80°C until assay.
* Levels of NT-Pro BNP and Neopterin were detected using ELISA kits as prescribed by manufacturer.
* Statistical tests appropriate to the study will be conducted to evaluate significance of results
* Results, conclusion, discussion and recommendations will be given

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

double-blind study

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ivabradine

Patients administered Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability.

Patients were followed up after 1 week of initiation of ivabradine therapy then monthly till the end of the study.

Group Type ACTIVE_COMPARATOR

Ivabradine Oral Tablet

Intervention Type DRUG

Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.

Control

Patients administered a placebo twice daily. Patients were followed up after 1 week of initiation of the study then monthly till the end of the study.

Group Type PLACEBO_COMPARATOR

Blacebo plus standard treatment

Intervention Type DRUG

Blacebo plus standard treatment

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ivabradine Oral Tablet

Ivabradine 5 mg twice daily and doses (2.5, 5, 7.5 mg) were to be adjusted upwards or downwards at every visit according to HR at rest and tolerability plus their standard treatment.

Intervention Type DRUG

Blacebo plus standard treatment

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Procoralan 5 mg film-coated tablets

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with chronic HF, on optimized medical therapy according to European Society of Cardiol¬ogy guidelines, with LV ejection fraction (LVEF) \< 35% according to the Simpson method, New York Heart Association (NYHA) class II-III, and sinus rhythm and resting HR \> 70/min were eligible for inclusion in the study.

Exclusion Criteria

* acute decompen¬sation (acute coronary syndromes and acute HF);
* hemodynamically significant valve disease;
* cer¬ebrovascular events during the previous 6 months;
* dysfunctional prosthetic heart valve;
* obstructive or non-obstructive cardiomyopathy; uncorrected congenital heart disease; active myocarditis;
* a his¬tory of resuscitation from sudden death; an absence of stable sinus rhythm, severe arrhythmias; HR \< 60 bpm; sick sinus syndrome; second-degree and third-degree atrioventricular block;
* severe obesity (body mass index \> 36 kg/m²);
* established or sus¬pected pulmonary diseases (vital capacity \< 80% or forced expiratory volume in 1 s \< 80% of age spe¬cific and sex-specific reference values);
* hemoglobin ≤ 11 g/dL;
* treatment with non-dihydropyridine calcium-channel blockers, class I antiarrhythmic agents, strong inhibitors of cytochrome P450-3A4, or QT interval-prolonging medications;
* acute and chronic kidney failure;
* pregnancy; hypo- and hy¬perthyroidism or acute infections.

Minimum Eligible Age

30 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No